key: cord-0940203-wttoschs
authors: Caliskan, Yasar; Axelrod, David; Guenette, Alexis; Lam, Ngan N.; Kute, Vivek; Alhamad, Tarek; Schnitzler, Mark A.; Lentine, Krista L.
title: COVID‐19 vaccination timing and kidney transplant waitlist management: An international
date: 2021-11-19
journal: Transpl Infect Dis
DOI: 10.1111/tid.13763
sha: dc6e692a4f207f0c588bb5359bb313734cb0b0ce
doc_id: 940203
cord_uid: wttoschs

BACKGROUND: The coronavirus disease 2019 (COVID‐19) pandemic has created unprecedented challenges for solid organ transplant programs worldwide. The aim of this study is to assess an international perspective on challenges faced by kidney transplant programs. METHODS: We administered an electronic survey instrument from 03/01/2021 to 08/06/2021 to staff at transplant programs outside the United States that comprised of 10 questions addressing the management of kidney transplant candidates with asymptomatic COVID‐19 infection or unvaccinated who receive an organ offer. RESULTS: Respondents (n = 62) represented 19 countries on 5 continents. Overall, 90.3% of respondents encourage vaccination on the waiting list and prior to planned living donor transplant. 12% of respondents reported that they have decided to inactivate unsensitized candidates (cPRA<80%) until they received the two‐dose of vaccination, and 7% report inactivating candidates who have received their first vaccine dose pending receipt of their second dose. The majority (88.5%) of international respondents declined organs for asymptomatic, nucleic acid testing (NAT)+ patients during admission without documented prior infection. However, 22.9% of international respondents proceeded with kidney transplant in NAT+ patients who were at least 30 days from initial diagnosis with negative chest imaging. CONCLUSIONS: Practitioners in some countries are less willing to accept deceased donor organs for waitlist candidates with incomplete COVID‐19 vaccination status and to wait longer before scheduling living donor transplant, compared to U.S. practices. Access to vaccinations and other resources may contribute to these differences. More research is needed to guide the optimal approach to vaccination before and after transplant. This article is protected by copyright. All rights reserved

The coronavirus disease 2019 (COVID-19) pandemic is a global challenge that requires an international response. 1 We recently conducted a national survey of U.S. kidney transplant programs and found that despite recommendations, 2,3 very few U.S centers are requiring pretransplant COVID-19 vaccination. In contrast to immunocompetent participants in vaccine trials, 4,5 solid organ transplant recipients have low immunization rates after receiving two doses of messenger RNA (mRNA)-based vaccines. 1, 6 Immunosuppressive drugs appear to attenuate the immune response to vaccination in kidney transplant recipients. 6 Many centers are proceeding with transplant in patients with persistently positive COVID-19 tests after clinically resolved infection, based on presumption that sustained positive tests reflect prolonged viral shedding rather than active infection, although uncertainty remains. 7 The landscape of practice continues to evolve with emerging data on the benefits of vaccine boosters in the immunosuppressed population. [8] [9] [10] These complex considerations have created operational challenges for decision-making related to the timing of transplantation in relation to vaccination and recovery from COVID-19 infection. To capture a broadened perspective from practitioners in other parts of the world, we designed and administered the electronic survey successfully used among U.S. programs, 7 to staff (nephrologists, surgeons, coordinators, other staff) at kidney transplant programs outside the United States from 03/01/2021-08/06/2021.

The survey instrument comprised of 10 questions addressing the management of kidney transplant candidates with asymptomatic COVID-19 infection who receive an organ offer as well as deceased donor transplant candidates who are not yet vaccinated ( Table 1) . The survey also queried This article is protected by copyright. All rights reserved.

information on the participant role (nephrologist, transplant surgeon, clinical coordinator, social worker, administrator, or other) at the transplant center. This study was approved by the Saint Louis University Institutional Review Board.

The target population was healthcare providers at active international kidney transplant centers.

United States (U.S.) results were collected first and reported separately. 7 International participants were recruited from kidney transplant programs in Africa, Asia, Europe, North and South America.

Potential participants were derived from the investigators' professional connections and the survey was emailed through the Qualtrics Survey Software. Opportunity for self-elected participation through a Qualtrics link was also posted to professional society list servs including that of the American Society of Transplantation (AST) Outstanding Questions in Transplantation (which includes international membership), the Turkish Society of Nephrology, and the Canadian Blood Services Living Donation Advisory Committee.

Each program was represented only once in the analysis. For programs with multiple respondents, we selected a single participant to represent the program using our algorithm in previous studies. 7 Responses to each survey question were described with percentages and frequencies. To obtain rates, we divided the number of program responses by the total number of programs who responded to the question, such that percentages reflect proportions of respondents, as per previous methods. 1, 7 For questions where participants were asked to "select all that apply," the denominator for calculating percentages was the number of participants responding to that question. All analyses were performed using R for windows version 1.2.5042 (RStudio Inc., Boston, MA).

Respondents (n=62) represented 19 countries on 5 continents. The majority of the participants were transplant nephrologists (75.8%), followed by transplant surgeons (8.1%), coordinators (3.2%) and pharmacists (3.2%), while 9.9 were other transplant professionals.

Overall, 90.3% of respondents at international centers encourage vaccination for all patients on the waiting list and prior to planned living donor transplants (Table 1) . Twelve percent of respondents reported that they have decided to inactivate unsensitized candidates (cPRA<80%) until they This article is protected by copyright. All rights reserved. received the two-dose of vaccination, and 7% report inactivating candidates who have received their first vaccine dose pending receipt of their second dose. Management of organ offers for asymptomatic patients who were found to be COVID-19+ with and without prior infection are similar in U.S. 7 and international survey responses. International participants appeared more conservative for deceased donor acceptance among waitlisted patients in the context of the pandemic.

Inactivation of patients with cPRA <80% until they receive a complete two-dose vaccine course was higher in international participants compared to U.S. participants (11.7% vs 1.1%) ( Figure   1A ). Acceptance of organs for unvaccinated patients who are not highly sensitized, followed by vaccination 4-12 weeks after transplant, was also a less common practice in international compared to U.S. centers (66.7% vs 83.7%). Although none of the U.S. centers reported inactivating highly sensitized patients with cPRA ≥80% until they receive complete two-dose vaccine course, 16.9% of international participants inactivate these highly sensitized patients pending complete vaccination ( Figure 1B) . More than half of the international respondents (52.5%) wait >4 weeks after completion of a recipient candidate's vaccination to schedule a living donor kidney transplant, while 35.8% of U.S. respondents wait >4 weeks. Regarding deceased donor transplants, most of the international respondents (87.5%) recommend recipients to wait >4 weeks after deceased donor transplant to receive their first dose of COVID-19 vaccination. The majority (88.5%) of international respondents declined organs for asymptomatic patients without documented prior infection who were found to have positive nasopharyngeal swab nucleic acid testing (NAT)+ during admission for transplant.

However, 22.9% of international respondents proceeded with kidney transplant in NAT+ patients on admission who were at least 30 days from initial diagnosis with negative chest imaging (Table 1 ).

COVID-19 pandemic has been a global concern for public health and has overwhelming impacts on organ transplantation. 1, 5, 7 During the initial pandemic period, transplantation volume in the majority of the countries including United States, France and Spain were reduced as 51%, 90% and 87%, respectively. 11, 12 This profound impact of COVID-19 on transplantation may have potentially devastating effects on patients on transplant waitlist. The results of this international survey suggest that practitioners in some countries are less willing to accept deceased donor organs for waitlist candidates with incomplete COVID-19 vaccination status and to wait longer before scheduling living donor transplant, compared to U.S. practices. These practice differences may be impacted by lower COVID-19 vaccination rates compared to United States in the participant countries and differences in access to supportive care in the event that a patient contracts COVID-19 after transplantation. 13 This article is protected by copyright. All rights reserved.

While the number of respondents was limited, a broadened perspective can be drawn from this survey results. Patients with end stage kidney disease may have more a robust response to vaccines before rather than after kidney transplant, 14 and when possible, SARS-CoV-2 vaccines should be given before transplantation. 14 In ideal way, transplant candidates should be tried to be completely vaccinated while they are awaiting transplant. In general, vaccines are recommended for completion at least 2 weeks prior to transplantation or starting at 1 month after transplantation. 14 Despite this recommendation even acceptance of organs for unvaccinated candidates followed by vaccination 4-12 weeks after transplant, was also a less common practice in international compared to U.S. centers. One sixth of international participants inactivate highly sensitized patients pending complete vaccination. More than half of the international respondents wait more than a month after completion of a recipient candidate's vaccination to schedule a living donor kidney transplant.

Access to vaccinations and other resources may contribute to these differences. Reliable access to timely, accurate information on the status of deceased donor viral infection is also essential to inform decisions on organ acceptance and ensure optimal organ utilization. 15 Vaccine mandate and management of patients who refuse vaccination is a timely and controversial topic. Our U.S study found that in Spring 2021, most U.S. transplant programs were encouraging vaccination but were not routinely delaying deceased donor transplant to complete a full vaccination. 7 This article is protected by copyright. All rights reserved.

In conclusion, transplant practitioners in some countries are less willing to accept deceased donor organs for waitlist candidates with incomplete COVID-19 vaccination status and to wait longer before scheduling living donor transplant, compared to U.S. practices. More research is needed to inform the risks and benefits of these practices, guide the optimal approach to vaccination before and after transplant including the emerging use of vaccine boosters, and the timing of transplantation in patients with recovered COVID-19 in all practice settings. [8] [9] [10] (14) Check antibody levels and if antibodies are present (suggesting immunity), proceed with transplant 16.4% (10) Other 13.1% (8) 'N=' Indicates the item denominator, based on number of respondents, and accounting for contingent responses

This article is protected by copyright. All rights reserved. 

An International survey on living kidney donation and transplant practices during the COVID-19 pandemic

Statement on COVID-19 Vaccination in Solid Organ Transplant Recipients

The Transplantation Society Transplant Infectious Disease Section. Guidance on Coronavirus Disease 2019 (COVID-19) for Transplant Clinicians

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Operational challenges in the COVID era: Asymptomatic infections and vaccination timing

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

This article is protected by copyright. All rights reserved

Organ procurement and transplantation during the COVID-19 pandemic

COVID-19-related collapse of transplantation systems: A heterogeneous recovery?

A global database of COVID-19 vaccinations

Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice

COVID-19 test result reporting for deceased donors: Emergent policies, logistical challenges, and future directions

OPTN (Organ Procurement and Transplantatio Network) Summary of Current Evidence and Information -Donor SARS-CoV-2 Testing & Organ Recovery from Donors with a History of COVID-19

The authors thank survey respondents, including members of the Turkish Society of Nephrology 

The authors of this manuscript have no conflicts of interest to disclose as described by Clinical Transplantation journal

Data availability is limited to aggregate summaries as reported, based on IRB requirements. This article is protected by copyright. All rights reserved.